---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033516"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:29:03.016675+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tivic Health raises ~$2.1M in public offering of 51.25M shares at $0.04/share

## Summary
- Offering of 51,250,000 shares priced at $0.040 per share, gross proceeds ~$2.1M.
- Net proceeds ~$1.9M after placement agent fees and expenses; intended for working capital.
- Maxim Group acted as placement agent, receiving 8% cash fee ($164,000) and 2,050,000 warrants.
- Placement agent warrants exercisable at $0.048/share for 5 years, 6-month lockout from closing.
- Officers and directors entered 30-day lock-up on company securities following closing.

## SEC filing metadata
- accession: 0000950170-23-033516
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/0000950170-23-033516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/tivc-20230714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033516
- JSON: https://secwatch.observer/filing/0000950170-23-033516.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033516.txt

## Key facts
- Material Agreements
  Valion Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2023-07-14).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Maxim Group LLC
  - Effective: 2023-07-14
  source text: Maxim Group LLC agreed to act as the placement agent (the “Placement Agent”), on a “reasonable best efforts” basis, in connection with the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/0000950170-23-033516-index.htm
- Material Agreements
  Valion Bio, Inc. entered into Purchase Agreement with the investors named on the signature pages thereto (the “Purchasers”) valued at approximately $2.1 million (effective 2023-07-14).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: the investors named on the signature pages thereto (the “Purchasers”)
  - Value: approximately $2.1 million
  - Effective: 2023-07-14
  source text: On July 14, 2023, Tivic Health Systems, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the investors named on the signature pages thereto (the “Purchasers”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787740/000095017023033516/0000950170-23-033516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.